IPSEN news, videos and press releases
For more news please use our advanced search feature.
IPSEN - More news...
IPSEN - More news...
- Ipsen S.A. publishes its 2024 consolidated financial statements
- Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
- Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
- Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGS
- Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus
- Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
- Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
- IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024
- Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
- Ipsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
- Half-year statement of IPSEN liquidity agreement - 2024 06 30
- IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
- IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
- Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
- Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
- Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
- Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024
- Ipsen appoints Keira Driansky as EVP, President of North America
- Ipsen publishes its 2023 Universal Registration Document
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
- Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
